ARS Pharmaceuticals (SPRY) Non-Current Deffered Revenue (2021 - 2026)

ARS Pharmaceuticals (SPRY) has 5 years of Non-Current Deffered Revenue data on file, last reported at $978000.0 in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue fell 26.96% year-over-year to $978000.0; the trailing twelve-month figure through Mar 2026 stood at $978000.0 (down 26.96% YoY), and the FY2025 full-year result was $1.1 million, down 26.24% from the prior year.
• Non-Current Deffered Revenue declined to $978000.0 in Q1 2026, from $1.1 million in the prior quarter.
• In the past five years, Non-Current Deffered Revenue ranged from a high of $2.9 million in Q4 2022 to a low of $978000.0 in Q1 2026.
• A 4-year average of $1.5 million and a median of $1.3 million in 2025 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue slipped 4.74% in 2022 and slipped 26.96% in 2026, its largest moves.
• Tracing SPRY's Non-Current Deffered Revenue over 4 years: stood at $2.9 million in 2022, then slumped by 46.32% to $1.5 million in 2024, then retreated by 26.24% to $1.1 million in 2025, then retreated by 13.45% to $978000.0 in 2026.
• Business Quant data shows SPRY's Non-Current Deffered Revenue at $978000.0 in Q1 2026, $1.1 million in Q4 2025, and $1.3 million in Q3 2025.